TNFRSF8 and Hodgkins lymphoma: In phase I clinical trials, antitumor responses have been observed in the presence or absence of conditioning chemotherapy when patients with brentuximab-refractory HL and ALCL patients were treated with anti-CD30 CAR T-cells containing a CD28 (74) or 4-1BB costimulatory domain (75).